Eunice Wang, MD

PrintE-mail
Associate Professor, Department of Medicine
Assistant Member, Tumor Immunology Program
Roswell Park Cancer Institute
Research Assistant Professor
Academic Scholar
School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise: 
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
Hematologic Oncology
Myelodysplastic syndrome (MDS)
Myeloproliferative diseases (MPD)

Research

Research Interests: 
Role of angiogenesis and hypoxia in promoting acute leukemia
Genetic analyses of leukemias

Background Information

Education and Training: 
MD - Keck School of Medicine, University of Southern California, Los Angeles, CA
Residency: 
Yale-New Haven Hospital, Yale University, New Haven, CT
Board Certification: 
Internal Medicine, American Board Internal Medicine
Hematology, American Board Internal Medicine
Medical Oncology, American Board Internal Medicine
Fellowships: 
Memorial Sloan Kettering Cancer Institute, New York, NY

Publications

Publications: 
  • Francis J, Spangenthal E, Cohen IL, McCarthy PL, Smiley S, Paplham P, Wang E, Wetzler M, Ahluwalia MS, Battiwalla M. Reversible cardiotoxicity with tyrosine kinase inhibitors. Clinical advances in hematology and oncology : H&O 2010; 8(2):128-132
  • Ngamphaiboon N, Sweeney R, Wetzler M, Wang ES. Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: Case report and review of the literature. Leukemia research 2010; 34(8):e194-6
  • Nowak NJ, Wang ES, Wallace PK, Ford L, Liu S, Gaile D, Deeb G, Zeidan A, Sait SNJ, Wetzler M. Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer genetics and cytogenetics 2010; 199(1):15-20
  • Telang U, Lal D, Zagst PD, Fetterly GJ, Wang ES. Investigation of the mechanism of aflibercept mediated modulation of doxorubicin anti-tumor effects in a preclinical model of leukemia: Development of a pharmacokinetic-pharmacodynamic model to guide combination dosing strategies. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:869
  • Varadarajan R, Cummings MK, Hyland AJ, Wang ES, Wetzler M. Can decreasing smoking prevalence reduce leukemia mortality?. Annals of hematology 2010; 89(9):873-876
  • , Nowak NJ, Wetzler M, Ford LA, Starostik P, Mashtare T, Gold D, Sait SNJ, Wang ES, Deeb G. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Cancer genetics and cytogenetics 2010; 202(2):101-107
  • Wetzler M, Wang E, Thompson J, Baer M, Block AM, Sait S, Barcos M, Tighe S, Ford LA, Andrews C, Baumann H. Priming with arsenic trioxide improves the outcome of newly diagnosed acute myeloid leukemia patients < 60 years old treated with high-dose cytarabine and idarubicin. Haematologica 2010; 95(Suppl. 2):Abstract #64
  • Pailler M, Johnson TM, Wang ES, Wetzler M. Marital satisfaction, social support and distress among patients with acute leukemia and their caregivers: a longitudinal study. Annals of behavioral medicine 2010; 39(Suppl. 1):73
  • Kantarjian HM , Franklin JL , Hu K , Garcia-Manero G , Gabrilove JL , Wang ES , Paquette RL , Greenberg PL , Giles FJ , Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010; 116(17):3163-3170
  • Lal D , Fetterly GJ , Wetzler M , Prey J , Murphy M , Mashtare TJ , Tian L , Lin M-H , Perez AM , Marinaro J , Demock K , Park JA , Wang ES. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Molecular cancer therapeutics 2010; 9(10):2737-2751
  • Brady MT, Lee J, Ferrone S, Wang ES, Wetzler M. Interferon-gamma secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. Leukemia research 2011; 35(2):275-277
  • Saranadasa M, Wang ES. Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. Cytokine 2011; 53(2):115-129
  • Attar EC, Moser BK, Stone RM, Booth A, Blum W, Wang ES, Voorhees PM, Powell BL, Kolitz JE, DeAngelo DJ, Wadleigh M, Amrein PC, Donohue KA, Larson R. Phase II study of bortezomib added to standard daunorubicin and cytarabine induction and dose escalation of bortezomib with intermediate-dose cytarabine consolidation therapy for patients with previously untreated acute myeloid leukemia age 60-75 years: Cancer and leukemia group B (CALGB) study 10502. Blood 2010; 116(21):331
  • Brady MT, Miller A, Sait S, Ford LA, Hans M, Wang ES, Lee KP, Baumann H, Wetzler M. Down-regulation of signal transducer and activator of transcription 3 enhances acute myeloid leukemia-derived dendritic cell function. Blood 2010; 116(21):3140
  • Lee HJ, Trump D, Johnson CS, Wang ES, Thompson JE, Griffiths EA, Vigil CE, Barcos M, Block A, Sait S, Ford LA, Wilding G, Wei T, Muindi J, Wetzler M. Subnormal vitamin D levels are associated with adverse outcome in newly-diagnosed similarly-treated adult acute myeloid leukemia (AML) patients. Blood 2010; 116(21):Abstract #1041
  • Block AW, Thompson JE, Wang ES, Starostik P, Deeb G, Sait SN, Ford L, Wilding GE, Groman AE, Wetzler M. The role of FLT3 in sole trisomy 8 acute myeloid leukemia. Journal of clinical oncology 2010; 28(15 Suppl.):6562
  • Drake AS, Brady MT, Wang XH, Sait SJN, Earp JC, Ghoshal S, Ferrone S, Wang ES, Wetzler M. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer immunology, immunotherapy : CII 2009; 58(3):415-427
  • Harb A, Tan W, Wilding GE, Battiwalla M, Sait SNJ, Wang ES, Wetzler M. Acute myeloid leukemia and diabetes insipidus with monosomy 7. Cancer genetics and cytogenetics 2009; 190(2):97-100
  • Harb AJ, Wang ES, Wallace PK, Barcos M, Block AW, Sait SNJ, Ford L, Wilding GE, Tan W, Wetzler M. Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models. Cancer 2009; 115(11):2472-2481
  • Varadarajan R, Ford L, Sait SNJ, Block AW, Barcos M, Wallace PK, Ramnath N, Wang ES, Wetzler M. Metachronous and synchronous presentation of acute myeloid leukemia and lung cancer. Leukemia research 2009; 33(9):1208-1211
  • Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand?. Expert opinion on biological therapy 2009; 9(1):111-119
  • O'Donnell MR, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Maslak P, Marcucci G, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Wang ES. Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 9(3):280-317
  • Almyroudis NG, Wetzler M, McCarthy PL Jr, Wang ES, Wongkittiroch K, Hazamy PA, Samonis G, Hahn T, Lesse AJ, Segal BH. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infection control and hospital epidemiology 2011; 32(5):490-496
  • Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, Wetzler M, Mashtare T, Wang ES. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leukemia research 2011; 35(5):579-584
  • Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011; 117(8):1583-1594
  • Levis M, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Nagler A, Lewis ID, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117(12):3294-3301
  • Noor SJ, Wang ES, Thompson JE, Block AW, Sait SN, Barcos M, Ford LA, Wilding GE, Tan W, Wetzler M. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. Leukemia research 2011; 35(5):608-613
  • Vigil CE, Griffiths EA, Wang ES, Wetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood reviews 2011; 25(3):139-146
  • O'Donnell MR, Moore JO, Ravandi F, Schuening F, Shami P, Smith BD, Stone RM, Tallman MS, Wang E, Millenson M, Maslak PG, Appelbaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, White FL. Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : JNCCN 2008; 6(10):962-993
  • Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases. Annals of oncology 2008; 19(9):1634-1638
  • Abdelhalim A, Barcos M, Block AW, Sait SN, Starostik P, Wetzler M, Wang ES. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leukemia and lymphoma 2007; 48(5):1053-1056
  • Wang ES, Wetzler M. Targeting CD40. Leukemia and lymphoma 2007; 48(2):229-231
  • Zeidan A, Wang ES, Wetzler M. What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response. Clinical advances in hematology and oncology : H&O 2008; 6(9):673-683
  • Faderl S, Wetzler M, Rizzieri D, Schiller GJ, Jagasia MH, Stuart RK, Ganguly S, Avigan D, Craig M, Collins R, Maris MB, Kovacsovics T, Goldberg S, Seiter K, Hari P, Ravandi F, Wang ES, Eckert S, Huebner D, Kantarjian H. Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6503
  • Vigil CE, Tan W, Wilding GE, Garcia-Manero G, Wang ES, Wetzler M, List AF. Comparison of outcome in erythroleukemia patients treated with standard chemotherapy regimens or hypomethylating agents : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6630
  • Demock KM, Marinaro J, McInnis I, Ford LA, Wetzler M, Tian L, Deeb G, Wang ES. Hypoxia-Inducible Factor-1 Alpha (HIF-1 alpha) and HIF-2 alpha Are Independent Prognostic Factors for Normal Karyotype Acute Myeloid Leukemia (NK AML). Blood 2008; 112(11):887
  • Demock KM, Marinaro J, Sobczyk A, Ford LA, Wetzler M, Deeb G, Tian L, Wang ES. Expression of Vascular Endothelial Growth Factor Receptors VEGFR-1 and VEGFR-2 Are Prognostic Factors in Normal Karyotype Acute Myeloid Leukemia (NK-AML). Blood 2008; 112(11):886-887
  • Doro NC, Lal D, Rustum Y, Wang ES. Selenium enhances the anti-angiogenic effects of bevacuzimab (Anti-VEGF antibody) in human acute myeloid leukemia xenograft models. Blood 2007; 110(11 Part 2):121B-122B (Abstract #4216)
  • Hsu YC, Lal D, Lamson A, Vargas R, Wang ES. Hypoxia-Induced Chemoresistance to Doxorubicin in Acute Myeloid Leukemia (AML) Cells Occurs Via HIF-1 alpha Independent Mechanism. Blood 2009; 114(22):1075
  • Kantarjian H, Giles F, Greenberg P, Paquette R, Wang E, Gabrilove J, Garcia-Mancro G, Gray J, Hu K, Franklin J. Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine. Blood 2008; 112(11):89-90
  • Lal D, Murphy M, Prey J, Fetterly GJ, Wang ES. VEGF-Trap (aflibercept) improves systemic delivery of doxorubicin to marrow and extramedullary leukemia sites in a preclinical model. Proceedings of the American Association for Cancer Research Annual Meeting 2009; 50:484-485
  • Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Jedrzejczak WW, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse. Blood 2009; 114(22):325-326
  • McInnis I, Hahn T, Ioane A, Larnson A, Lal D, Ford LA, Sait SNJ, Starostik P, Deeb G, Wetzler M, Mashtare T, Wang ES. Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML). Blood 2009; 114(22):1208
  • Noor S, Tan W, Wilding G, Ford LA, Barcos M, Sait SNJ, Block AW, Thompson JE, Wang ES, Wetzler M. Myeloid Blastic Transformation of Myeloproliferative Neoplasms - A Review of 113 Cases. Blood 2009; 114(22):1210
  • Shivakumar R, Tan W, Wilding G, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia - Review of 101 cases. Blood 2007; 110(11 Part 2):154B (Abstract #4345)
  • Varadarajan R, Licht A, Hyland AJ, Ford LA, Barcos M, Sait SNJ, Block AW, Baer MR, Thompson JE, Wang ES, Wetzler M. Smoking Adversely Affects Survival in Acute Myeloid Leukemia Patients. Blood 2009; 114(22):407
  • Wang ES, Sobczyk A, Marinaro JM, Wetzler M, Tian L, Deeb G. VEGF-A, VEGF-C, and CD31 expression by leukemia cells are prognostic factors for overall survival in acute myeloid leukemia (AML). Blood 2007; 110(11 Part 1):Abstract #2392
  • Zeidan A, Gaile D, Conroy JM, McQuaid DE, Wang ES, Deeb G, Wallace PK, Sait SNJ, Nowak NJ, Wetzler M. Frequent molecular aberrations in normal karyotype (NC) precursor B-cell acute lymphoblastic leukemia (pB-ALL) detected by comparative genomic hybridization. Blood 2007; 110(11 Part 2):135B (Abstract #4270)
  • Zeidan A, Tan W, Wilding G, Ford L, Hahn T, Smiley S, Battiwalla M, McCarthy PL, Wang ES, Wetzler M. Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT). Blood 2008; 112(11):350-351
  • Lee HJ, Wright KM, Kandeel E, Tan W, Wilding GE, Ford LA, Sait SN, Block AMW, Barcos MP, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. The role of minimal residual disease (MRD) by flow cytometry (FC) in predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) patients : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6592
  • Smonskey M, Starostik P, Deeb G, Demock K, Vargas R, Lal D, Sait SN, Wetzler M, Wang ES. Association of IDH1 mutations in normal karyotype acute myeloid leukemia samples with higher HIF-1{alpha} and VEGF-A expression : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6530
  • Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H. Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer 2011; 117(21):4861-4868
  • Lee HJ, Licht AS, Hyland AJ, Ford LA, Sait SN, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Is obesity a prognostic factor for acute myeloid leukemia outcome?. Annals of hematology 2012; 91(3):359-365
  • Liu H, Zhang YL, Hahn T, Thomas J, Wetzler M, Wang ES, Hernandez L, Ross M, Chen GL, McCarthy PL. Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood 2011; 118(21):1338
  • Varadarajan R, Licht AS, Hyland AJ, Ford LA, Sait SNJ, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Smoking adversely affects survival in acute myeloid leukemia patients. International journal of cancer 2012; 130(6):1451-1458
  • Wang ES, Agwa E, Zhang SX, Merzianu M. Acute Leukemias of Ambiguous Lineage: The Roswell Park Experience. Blood 2011; 118(21):1092
  • Wang ES, Pili R, Seshadri M. Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. Journal of clinical oncology 2012; 30(7):760-761
  • Jarkowski A 3rd, Forrest A, Sweeney RP, Tan W, Segal BH, Almyroudis N, Wang ES, Wetzler M. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. Journal of oncology pharmacy practice 2012; 18(1):91-96
  • Aras UT, Lal D, Zagst P, Fetterly GJ, Wang ES. Development of a pharmacokinetic (PK)-pharmacodynamic (PD) model to guide combination-dosing strategies of aflibercept (VEGF Trap) and doxorubicin chemotherapy in a systemic preclinical model of human acute myeloid leukemia. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #5463
  • Damodaran S, Bellavia T, Sait SNJ, Wang ES, Wetzler M, Khushalani NI. Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. Clinical colorectal cancer 2012; 11(2):151-154
  • Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees PM, Wang ES, Blum WG, Marcucci G, Bloomfield CD, Moser BK, Stone RM, Larson RA, CALGB . A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6526
  • Vigil CE, Griffiths EA, Thompson JE, Tan W, Greene J, Ford LA, Wang ES, Wetzler M. A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6602
  • Minderman H, Arcadi JC, Wierzbicki A, Wang ES, Sait SNJ, Block AW, Liang L, George T, Wallace PK. Detection of Numerical Chromosome Aberrations in Rare Acute Myeloid Leukemia (AML) Cells. Haematologica 2009; 94(Suppl. 2):0037
  • Sardesai SD, Tan W, Ford LA, Deeb G, Block AMW, Sait SNJ, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6565
  • Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. Journal of clinical oncology 2012; 30(20):2492-2499
  • Wang ES, Yee K, Koh LP, Hogge D, Enschede S, Carlson DM, Dudley M, Glaser K, McKeegan E, Albert DH, Li X, Pradhan R, Stock W. Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leukemia and lymphoma 2012; 53(8):1543-1551
  • Minderman H, Humphrey K, Arcadi JK, Wierzbicki A, Maguire O, Wang ES, Block AW, Sait SN, George TC, Wallace PK. Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension. Cytometry. Part A 2012; 81A(9):776-784
  • O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM. Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(8):984-1021
  • Wang ES, Zeidan A, Tan W, Wilding GE, Ford LA, Wallace PK, Hahn TE, Battiwalla M, McCarthy PL, Wetzler M. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. Leukemia and lymphoma 2012; 53(10):2085-2088